Skip to main content
HEM Pharma Inc. logo

HEM Pharma Inc. — Investor Relations & Filings

Ticker · 376270 ISIN · KR7376270005 KO Manufacturing
Open in API
Filings indexed 93 across all filing types
Latest filing 2025-03-21 Annual Report
Country KR South Korea
Listing KO 376270

About HEM Pharma Inc.

https://hempharma.bio/

HEM Pharma Inc. is a biotechnology company specializing in microbiome-based healthcare solutions. The company researches and develops Live Biotherapeutic Products (LBPs), health functional foods, and other bio-products derived from human-effective microbes. A core component of its R&D is the proprietary Pharmaceutical Meta-Analysis System (PMAS), a technology platform that simulates the human gut microbiome to screen for and analyze beneficial microorganisms. In addition to its product pipeline, HEM Pharma provides personalized healthcare services based on microbiome analysis and offers Contract Development and Manufacturing Organization (CDMO) services for next-generation biological materials.

Recent filings

Filing Released Lang Actions
사업보고서 (2024.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 9th fiscal year (2024) of HEM Pharma Inc. It contains detailed company information, history, capital structure, business overview, and financial-related disclosures. This is a standard annual regulatory filing required by the Financial Supervisory Service (FSS) and Korea Exchange (KRX) in South Korea, which corresponds to the '10-K' (Annual Report) category in the provided schema. FY 2024
2025-03-21 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (a Non-Deal Roadshow). It provides the date, location, and purpose of the meeting, and mentions that IR materials will be made available on the KRX KIND system. Since it is an announcement of an event and the availability of materials rather than the presentation itself, and it fits the criteria for a regulatory announcement regarding corporate activities, it is classified as a Regulatory Filing (RNS).
2025-03-21 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for HEM Pharma. It contains the meeting agenda, details on board member re-elections, financial statement approval, and management reports (including audit reports and business outlook). This type of document is standard for providing shareholders with the necessary information to vote at an upcoming Annual General Meeting. According to the provided definitions, materials shared for an AGM are classified as AGM-R.
2025-03-14 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (HEM Pharma) regarding a correction to a previously filed 'Change in Sales or Profit/Loss Structure' report. It details specific financial adjustments (revenue, operating profit, net income) due to the external audit process. This type of filing is a standard regulatory disclosure in the Korean market (DART system) for material financial changes, which falls under the 'Regulatory Filings' category as it is a specific corporate disclosure update. FY 2024
2025-03-13 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for HEM Pharma, detailing the date, location, and agenda items such as financial statement approval, board re-elections, and remuneration limits. This is a standard proxy solicitation document used to inform shareholders of the meeting and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2025-03-13 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a formal announcement regarding the scheduling of an Investor Relations (IR) event (기업설명회). It provides details such as the date, location, target audience, and purpose of the meeting. Since it is an announcement of an upcoming event rather than the presentation materials themselves, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a general regulatory filing/announcement.
2025-03-11 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.